Best Rheumatology Journals (2026): Ranked by Impact and Accessibility
A ranked guide to the top 12 rheumatology journals by impact factor, acceptance rate, APC, and review time, from Annals of the Rheumatic Diseases and Arthritis & Rheumatology to accessible options.
Senior Researcher, Oncology & Cell Biology
Author context
Specializes in manuscript preparation and peer review strategy for oncology and cell biology, with deep experience evaluating submissions to Nature Medicine, JCO, Cancer Cell, and Cell-family journals.
Next step
Choose the next useful decision step first.
Use the guide or checklist that matches this page's intent before you ask for a manuscript-level diagnostic.
Rheumatology has seen a publishing boom in the last decade, driven by biologics research, autoimmune disease epidemiology, and a deeper understanding of inflammatory pathways. The journal landscape reflects this growth. You'll find everything from elite society journals that only accept practice-changing trials to accessible open access titles that welcome well-designed observational studies and case series. The challenge isn't finding a journal. It's finding the right one for your specific manuscript.
One thing that sets rheumatology apart from larger specialties is the tight-knit community. Editors, reviewers, and readers often know each other from conferences. That means reputation matters, and publishing in the right journal can open doors to collaborations and speaking invitations. It also means desk rejections at top journals are common if your work doesn't clearly advance the field's most pressing questions.
Quick Answer: Top 5 Rheumatology Journals
- Nature Reviews Rheumatology (IF ~33.5) for commissioned reviews
- Annals of the Rheumatic Diseases (ARD) (IF ~20.6) for top-tier original research
- Arthritis & Rheumatology (IF ~10.9) for strong US-oriented research
- Rheumatology (Oxford) (IF ~7.2) for solid clinical work
- Arthritis Research & Therapy (IF ~5.2) for open access translational work
Full Comparison Table
Journal | IF | Acceptance Rate | APC | Review Time | Scope |
|---|---|---|---|---|---|
Nature Reviews Rheumatology | ~33.5 | <5% | $11,390 (OA option) | 4-8 weeks | Reviews only |
Annals of the Rheumatic Diseases | ~20.6 | ~8% | $4,100 (OA option) | 4-8 weeks | Clinical and translational |
Arthritis & Rheumatology | ~10.9 | ~10% | $3,800 (OA option) | 6-10 weeks | Original research, all rheumatology |
Lancet Rheumatology | ~15.5 | ~7% | $5,690 (OA) | 4-8 weeks | Clinical trials, high impact |
Rheumatology (Oxford) | ~7.2 | ~18% | $3,600 (OA option) | 6-10 weeks | Clinical research |
Seminars in Arthritis and Rheumatism | ~6.8 | ~20% | Subscription | 6-12 weeks | Reviews and clinical studies |
Arthritis Research & Therapy | ~5.2 | ~30% | $2,890 (OA) | 4-8 weeks | Translational, open access |
RMD Open | ~5.0 | ~28% | $2,700 (OA) | 4-6 weeks | Open access, EULAR affiliated |
Joint Bone Spine | ~4.5 | ~25% | $3,200 (OA option) | 6-10 weeks | French rheumatology society |
Lupus | ~2.8 | ~35% | $3,000 (OA option) | 6-10 weeks | Lupus-focused |
Journal of Rheumatology | ~4.1 | ~22% | Subscription | 8-12 weeks | Broad clinical rheumatology |
Clinical Rheumatology | ~2.6 | ~38% | $3,060 (OA option) | 4-8 weeks | Case reports, clinical studies |
Elite Tier: The Highest Bar
Nature Reviews Rheumatology
This journal publishes only review articles, commentaries, and perspectives, and almost all content is commissioned. You won't send original data here. But if you're recognized as an expert in your area, an editorial team invitation to write a review for Nature Reviews Rheumatology is one of the highest honors in the specialty. The reach extends well beyond rheumatology into immunology and internal medicine.
Annals of the Rheumatic Diseases (ARD)
ARD is the flagship of EULAR and arguably the most influential rheumatology journal for original research. It has an unusually high impact factor for a specialty journal, driven partly by its role in publishing EULAR recommendations and major clinical trial results. The review process is fast and rigorous. ARD favors papers that will change clinical practice or fundamentally shift understanding of rheumatic diseases. If you have a multicenter RCT or a large epidemiological study with clear clinical implications, ARD is the target.
Arthritis & Rheumatology
This is the ACR's flagship journal and the top US-based rheumatology title. It publishes strong original research across clinical, translational, and basic science domains. The journal has a slight preference for mechanistic work compared to ARD's clinical emphasis, which makes it a better fit for studies that bridge bench and bedside. Review quality is generally high, and the editorial team provides constructive feedback even on rejected manuscripts.
Lancet Rheumatology
Launched relatively recently as part of the Lancet family, this journal has quickly established itself as an elite venue for clinical rheumatology. It's fully open access with a corresponding APC, and it focuses on clinical trials, large cohort studies, and health policy research. The Lancet brand gives papers enormous visibility outside the specialty.
Strong Tier: Competitive and Respected
Rheumatology (Oxford)
The BSR's official journal is a consistent, well-edited publication that sits comfortably in the strong tier. It accepts a broader range of study designs than the elite journals and is particularly receptive to epidemiological work, systematic reviews, and clinical outcome studies. If your paper is solid but doesn't quite reach ARD's novelty threshold, Rheumatology is an excellent step down that won't feel like a compromise.
Seminars in Arthritis and Rheumatism
Despite its name suggesting review content, this journal also publishes original research. It's a good fit for thorough systematic reviews, meta-analyses, and large observational studies. The review process can be slow, but the journal carries genuine respect in the field, especially for review articles.
Journal of Rheumatology
JRheum is a Canadian journal with a long history and loyal readership. It publishes across all of clinical rheumatology and is particularly strong in outcomes research, disease registries, and validated measurement tools. The review process tends to be thorough but can be slow. A solid choice for well-designed clinical studies.
Accessible Tier: Realistic Targets with Good Visibility
Arthritis Research & Therapy
This BioMed Central journal is fully open access and has built a strong reputation for translational rheumatology research. It's a good home for well-designed studies that connect basic science findings to clinical outcomes. The acceptance rate around 30% is realistic for many research groups, and the OA model ensures broad readership.
RMD Open
EULAR's open access journal was created as a companion to ARD, and it's established itself as more than a spillover venue. It publishes original research, systematic reviews, and recommendations with a European focus. The connection to EULAR gives it visibility at conferences, and the APC is reasonable by current standards.
Joint Bone Spine
The French Society of Rheumatology's journal publishes solid clinical research with a European perspective. It's a reasonable target for single-center studies, cohort analyses, and observational research. The journal is indexed in all major databases and has a stable readership.
Clinical Rheumatology
If you need a home for well-written case reports, small cohort studies, or regional epidemiological work, Clinical Rheumatology is a pragmatic choice. The acceptance rate is higher than most, and the turnaround is predictable. It's not glamorous, but it's indexed, read, and cited.
Lupus
This disease-focused journal is the natural home for lupus research that doesn't reach the generalist rheumatology journals. It covers clinical, translational, and epidemiological aspects of SLE and related conditions. If your study population is specifically lupus patients, consider Lupus before a generalist title where your work might get lost.
Decision Framework: Matching Your Paper
If your paper is a large multicenter RCT, ARD or Lancet Rheumatology should be your first targets. Both prioritize practice-changing clinical evidence.
If your paper connects basic science to clinical outcomes, Arthritis & Rheumatology is ideal. It values mechanistic work more than other top journals in the field.
If your paper is a well-designed observational study, Rheumatology (Oxford) or Journal of Rheumatology offer good fits. Both welcome epidemiological and outcomes research.
If your paper is a systematic review or meta-analysis, Seminars in Arthritis and Rheumatism has long been the preferred venue. RMD Open is also increasingly receptive.
If your paper needs open access and you have limited funding, RMD Open and Arthritis Research & Therapy both offer reasonable APCs with strong visibility.
If your paper is disease-specific (lupus, vasculitis, scleroderma), consider specialty journals like Lupus before generalist titles. Your audience is already reading there.
Common Mistakes in Rheumatology Journal Selection
Overestimating novelty for ARD. Many researchers send their best work to ARD first without realizing the journal receives thousands of submissions annually and desk-rejects the majority. If your study isn't clearly practice-changing, you may waste months.
Ignoring the transatlantic divide. ARD and RMD Open lean European. Arthritis & Rheumatology and Journal of Rheumatology lean North American. Your study population and healthcare context should match.
Sending bench science to clinical journals. Rheumatology (Oxford) and Journal of Rheumatology are clinical titles. If your paper is primarily about T-cell subsets in murine models, these journals will redirect you.
Treating OA journals as lesser. Arthritis Research & Therapy has an IF over 5 and excellent visibility. RMD Open has EULAR backing. These aren't consolation prizes. They're strategic choices.
Neglecting formatting requirements. Rheumatology journals have specific word limits, figure requirements, and structured abstract formats. Not following these signals carelessness to editors.
Get Your Manuscript Ready
Before submitting to any rheumatology journal, make sure your manuscript meets the specific formatting and quality standards your target journal expects. Running your paper through Manusights' AI-powered review can identify structural weaknesses, flag missing statistical details, and help you align your abstract with what editors want to see. In a field where desk rejection rates are high, every detail counts.
Sources
Reference library
Use the core publishing datasets alongside this guide
This article answers one part of the publishing decision. The reference library covers the recurring questions that usually come next: how selective journals are, how long review takes, and what the submission requirements look like across journals.
Dataset / reference guide
Peer Review Timelines by Journal
Reference-grade journal timeline data that authors, labs, and writing centers can cite when discussing realistic review timing.
Dataset / benchmark
Biomedical Journal Acceptance Rates
A field-organized acceptance-rate guide that works as a neutral benchmark when authors are deciding how selective to target.
Reference table
Journal Submission Specs
A high-utility submission table covering word limits, figure caps, reference limits, and formatting expectations.
Before you upload
Choose the next useful decision step first.
Move from this article into the next decision-support step. The scan works best once the journal and submission plan are clearer.
Use the scan once the manuscript and target journal are concrete enough to evaluate.
Anthropic Privacy Partner. Zero-retention manuscript processing.
Where to go next
Supporting reads
Conversion step
Choose the next useful decision step first.
Use the scan once the manuscript and target journal are concrete enough to evaluate.